2D immunoblots show differential response of mouse IgG and IgM antibodies to antigens of mammary carcinoma 4 T1 cells

Mariana Díaz-Zaragoza¹,², Ricardo Hernández¹ and Pedro Ostoa-Saloma¹,²*

Abstract

Background: Immunosuppression in breast cancer has been reported in women and in the highly metastatic mouse mammary tumor model 4 T1. The immunosuppressive environment complicates the use of the humoral response against the tumor as an immunodiagnostic tool. IgM has not been used in immunodiagnostic in part because its antitumor responses, both innate and adaptive, have not been studied in function of time in breast cancer. We show a new approach to analyzing the mouse humoral immune response, and compare the evolution with time of IgG and IgM responses against the antigens of 4 T1 cells.

Methods: The study is based on 2-dimensional immunoblotting detection of antigens from 4 T1 cells by the IgG and IgM antibodies in the serum of female mice injected with 4 T1 cells.

Results: There was a high variability in the intra- and inter-mouse response. Variability in the IgM response was manifested as a pattern of spots that could become a multibinomial variable of 0 and 1, which could represent a signature of the immune response. Different numbers of spots was found in the IgG and IgM responses from week 1 to 5. On average, the IgM had more but the IgG response decrease with the time. The natural IgM at t = 0 responds stronger than w1; the adaptive response of both IgM and IgG were elicited where, with the former being stronger better than the latter. Antigens that are recognized by some female mice in the first week are also recognized by other female mice at time 0. Contamination of the natural IgM makes difficult use the adaptive IgM as a tool for immunodiagnostic.

Conclusions: IgM and IgG response varied with the time and individuals. Spot variation in 2D pattern for the natural IgM could be expressed as a binomial signature, which opens up the way to correlate a particular pattern with resistance or susceptibility. This uncovers a battery of IgMs for each individual to confront cancer or infections. The possibility to differentiate between adaptive IgM antibodies from the natural IgM will allow investigation of the adaptive IgM for early immunodiagnosis.

Keywords: 2D Immunoblot, IgM, 4 T1 cells, Mammary carcinoma

Background

During a lifetime, human beings are permanently exposed to the development of transformed cells, which arise spontaneously or by contact with trigger factors. Immune surveillance of cancer leads to the generation of anti-tumor antibodies from the early stages of the disease [1]. Once a tumor is established, however, the network of immune system associated with it, may paradoxically promote tumor growth and metastasis rather its destruction [2]. The use of mouse models allows investigation of how the immunosuppression status may contribute to tumor establishment. Immunosuppression in breast cancer occurs in women [3-5], and in the highly metastatic mouse mammary tumor model 4 T1 [6,7]. An immunosuppressive environment complicates the use of the humoral response against the tumor as an immunodiagnostic tool. Autoantibodies have many attractive features as biomarkers, in particular natural IgM antibodies (Ab) are involved in the primary defense mechanism that activates the cascades of complement and apoptosis. Therefore
Results and discussion

The images in Figure 1 of the 2D-immunoblots shows a remarkable variation among the humoral immune response mediated by IgG or IgM in each serum of individual female mice at t = 0 and during the 5 weeks of development of breast cancer. The number of antigens recognized by IgM in the first week was very similar that recognized in time 0 (518 and 563, respectively); however, the recognition pattern was different. In the analysis of IgM and IgG response with time, the Σ of IgM spots at t = 0 varied from 35 to 98 antigens, with an average of 62.6 and a standard deviation (sd) of 23.5 (Table 1). During the 5 weeks, the IgM response varied from 57.6 spots in the first week to 55.8 by the fifth week, with the lowest response (41 spots) in the third week. After challenge with 4 T1 tumor cells, the response IgG was, on average, the highest response at the first week (20.3 spots), but this was decreased with time. It can also be seen that 4 T1 antigen recognition by IgM is presented from week 0 (pre-immune serum), whereas there was no response of IgG (e.g. mice 1 and 2) or almost absent (e.g. mice 4 and 5). At 1 week after implantation of 4 T1 tumor cells, the IgG and IgM responses were still present; however, IgG recognition decays through to 5 weeks of tumor growth, so that the response of IgM is maintained at a higher level than IgG during tumor development. Decrease in the IgG response is possibly due to immunosuppression caused by the development of breast cancer at the time that the 4 T1 tumor cells were implanted [5]. Since the IgM response, also declined slightly in the number of spots with time, immunosuppression would also be affecting it. Decrease in the IgM response could be due to a T-independent immunosuppression, which is based on the existence of T-independent antigens as glycoproteins and glycolipids, which are recognized by natural IgM because they are capable of activating B cells without T cell collaboration [20-22]. Since the volume of serum was low, IgM could not be measured by ELISA because of even though fewer spots, the IgM concentration could be maintained, and then there would not be any immunosuppression.

At time 0, the difference in spots number between the IgG and IgM was clear, with the IgG spots being almost zero, and the IgM spots numerous. The pattern of spots in the IgM response at was highly variable, and there were no 2 similar immunoblots. Identification of 4 T1 antigen by IgM, even before antigenic challenge (t = 0), was consistent with an innate humoral recognition mentioned above, nature of this recognition being through structural patterns of Toll-like receptors. Carbohydrates are the main structures recognized, but there are also reports where the natural IgM can recognize the carboxyl terminus of proteins [23]. There were 2 types of IgM found in normal conditions in the circulation in mice. Natural IgM is mainly secreted by B-1a CD5+ cells in the apparent absence of antigen stimulation, which constitutes most of the circulating IgM [24], whereas antigen-induced IgM is mostly produced by conventional B (B-2) cells only after antigen stimulation [25]. Thus antibodies detected at time 0 are called natural antibodies. Variability in the IgM response was manifested as a pattern of spots that became a multibinomial variable of 0 and 1, which could represent a signature of the IgM or IgG humoral immune responses (Figure 2); each signature is therefore a measure of this variability. Each mouse has an individual pattern of recognition, in this case to the tumor antigenic background, manifested in tumor size (Table 2). Thus each individual has a unique expression of genetically determined natural IgMs (in number and capacity of recognition). The possibility that this genetic determination does not recognize different tumors and their cells in the same way, or that some individuals recognize some kind of tumor better than others, is being investigated.

The cancer model we used did not allow us to establish a relation between a natural IgM response and resistance to tumor because this model was originally one for studying metastasis. Another type of mouse model, where diverse stages of cancer can develop will allow us to correlate natural IgM response with resistance.
Figure 1 Images of 2D-immunoblot of the immune response mediated by IgG and IgM in female mice analyzed with PdQuest software. Images of T = 0 and w1-5 are shown. Scales of Molecular Weight (kDa) and isoelectric point (pH) are only shown in the images of 2D-immunoblot 1_IgG-T = 0. The red crosses indicate the center of each spot and the yellow circle, their area.
The pattern recognition of IgM after inoculation of 4 T1 cells is not only caused by acquired immune response, but by the innate immune response. Some antigens that are recognized in the first week are also recognized by the same female at time 0. It is possible that these antigens in the first week, and sharing IP and MW with time = 0, are a product of an adaptive IgM in response to 4 T1 cells. The number of spots in Table 1 from the first to the fifth week for each mouse is the result of subtracting the antigens recognized at t = 0, which by coincidence were also detected in subsequent times of tumor development by isoelectric point and molecular weight determinations. Hence, in Table 1 the spots exclusively produced by the innate immune response (t = 0), separated from the spots produced exclusively by the acquired immune response (t = w1-5), antigens that are shared over time, were not considered exclusive. The significant number of antigens was recognized by IgM at the first week, from which we could use several antigens for early diagnosis because they are the first to be recognized by IgM and IgG immunoglobulins after antigen challenge with 4 T1 tumor cells. However, the antigens that are mainly recognized are the one that overlapped between natural and adaptive IgM makes it difficult to use adaptive IgM as a diagnostic character of early immunodiagnostic. This difficulty could be overcome if technically one can distinguish structurally between natural IgM and adaptive IgM.

The number of spots in each 2D-immunoblot by immunoglobulin to the week of tumor development was estimated. Figure 3 gives frequency of spots of most of the antigens recognized, those half recognized and those barely recognized. The sum total of the spots of antigen recognition by natural IgM in the T = 0 was 563, and the frequency of spots for 8 antigens shared by all females

| N° female mice | w0 | w1 | w2 | w3 | w4 | w5 | Σ spots IgM T = w1–w 5 | TOTAL Σ spots IgM w0 – w5 |
|---------------|----|----|----|----|----|----|----------------|--------------------------|
| 1             | 86 | 20 | 129| 83 | 146| 75 | 453            | 539                     |
| 2             | 39 | 77 | 49 | 49 | 60 | 89 | 324            | 363                     |
| 3             | 65 | 66 | 41 | 18 | 24 | 31 | 180            | 245                     |
| 4             | 45 | 94 | 22 | 24 | 36 | 15 | 191            | 236                     |
| 5             | 98 | 69 | 63 | 91 | 61 | 13 | 297            | 395                     |
| 6             | 89 | 21 | 23 | 23 | 14 | 23 | 104            | 193                     |
| 7             | 45 | 28 | 19 | 14 | 70 | 144 | 275          | 320                     |
| 9             | 35 | 120| 109| 17 | 15 | 43 | 304            | 339                     |
| 10            | 61 | 23 | 47 | 46 | 78 | 69 | 263            | 324                     |

Σ spots by serum 563 518 502 365 304 297 2391 2954

Average 62.6 57.6 55.8 40.6 56.0 55.8 265.7 328.2

SD 23.6 36.4 39.0 29.2 41.4 43.0 100.1 328.2

| Σ spots by serum | 2391 | 2954 |
|------------------|------|------|
| Average          | 265.7| 328.2|
| SD               | 100.1| 328.2|

Table 1 Number, sum, average, standard deviation and total of spots found in 2D-immunoblot images of female mice from response mediated by IgG and IgM through the development of breast cancer with 4 T1 tumor cells
mice at week 0. At week 1 (w1), the sum for all females was 518, and the frequency of spots related to 10 shared antigens. However, by comparing the frequency of antigen recognition spots at T = 0 and T = w1, this was low, with only 10 antigens shared between the two from a total of 1081. With respect to above mentioned IgM, the IgG response was reduced in the first week (T = w1), but the frequency of antigens recognized was similar between the IgG and IgM responses, being 3 from 183 and 10 from 518 shared antigens between individuals, respectively. The frequency of recognition of IgM and IgG against the same antigens shows that there are very few antigens detected by IgM or IgG shared among the individuals at time 0 and week 1, or between IgG and IgM. But the fact that IgM and IgG match some antigens in w1 that are the early antigen recognized indicates that they are particularly remarkable; this antigenic “selection” by the host could be used as a criterion to determine antigens in further work. This shared recognition reinforces the idea of using this system to find antigens in the human population that have dual recognition, not only IgM (natural or adaptive) but IgG, which can be help develop an early diagnostic test.

### Conclusion

IgM and IgG responses against 4 T1 cells vary with the time and between individuals. Spots variation in 2D pattern for natural IgM can be expressed as a binomial signature, which opens the way to correlate a particular pattern with resistance or susceptibility. The possibility of differentiating between adaptive IgM antibodies from the natural IgMs should allow the study of the adaptive IgM as a tool for early immunodiagnosis.

### Methods

#### Mice and cell line

10 female BALB/c AnN mice 8 old-weeks were kept in the animal facilities at the Instituto de Investigaciones Biomédicas, UNAM. All experiments were carried out in accordance with the animal-welfare ordinance and approved by the Code of Ethics for Academic Staff of the Institute: (http://www.biomedicas.unam.mx/_administracion/reglamentos_formatos/archivos_pdf/CodigoIIBO.pdf).

The 4 T1 tumor cell line was grown in RPMI +10% Fetal Bovine Serum +1 X of antibiotic-antimycotic mixture (streptomycin, ampicillin) in culture dishes (25 cm²) incubated at 37°C in air plus 5% CO₂.
Implantation of tumor cells
BALB/c mice was shaved on the abdomen and injected with $10 \times 10^3$ 4 T1 tumor cells in 50 $\mu$L isotonic solution subcutaneously in a nipple of a mammary gland. The tumor was allowed to develop and grow for 30 days. Tumor size was measured after removal in 2 perpendicular dimensions with a Vernier caliper. Tumor size in cubic millimeters was calculated by the formula $(a \times b^2)/2$, where $b$ was the smaller dimension of the tumor.

Serum sampling
BALB/c mice were bled by the tail once per week for 6 weeks. The first bleeding was made before implanting 4 T1 tumor cells (time = 0) or pre-immune serum. After implantation of tumor cells, mice were bled and the sera weekly (w1, 2, 3, 4 and 5). Blood was incubated at 4°C for 30 min and centrifuged for storage at -20°C until use.

2D electrophoresis
For immunoblotting, proteins from 4 T1 cells were incubated with Abs from each serum of every mouse at different stages of tumor growth. A volume (100 $\mu$g) of 4 T1 cell proteins in 6 M urea, 50 mM DTT, 2% CHAPS, 2% ampholines pH 3-10 (Bio-Lyte), 0.001% bromophenol blue and MilliQ H$_2$O up to 125 $\mu$L was used to hydrate the IPG strips (7 cm) in an immobilized pH gradient (pHi 3-10, Bio-Rad). To separate proteins from the 4 T1 cells or tumors in one dimension (isoelectric point), hydrated strips were placed in the Protein IEF Cell from Bio-Rad reaching a voltage of 4000 and 10,000 V-h ~6 h.

After separation of proteins by isoelectric focusing, the strips were equilibrated with 2 washes for 10 min, the first in 6 M urea, 0.375 M Tris–HCl, pH8.8, 2% SDS, 20% glycerol, 2% (w / v) DTT, and the second in 6 M urea, 0.375 M Tris–HCl, pH8.8, 2% SDS, 20% glycerol, 2.5% (w / v) iodo-acetamide.

For the separation in a second dimension (2D) for molecular weight, the strip with separated proteins in one dimension was placed on an acrylamide gel (MiniPROTEAN TGX Precast Gels, 10-20%, Bio-Rad) and electrophoresed in buffer 25 mMTris pH 8.3, 250 mM glycine, 0.1%SDS, at 100 V for 90 min in a chamber (Mini-Protean Tetra Cell, Bio-Rad). The proteins separated on 2D were electrophoretically transferred to a nitrocellulose membrane using a wet transfer chamber (Mini Trans-Blot Cell, Bio-Rad) at 100 V, 1 h and 10 min; the buffer was Tris-Glycine-Methanol (25 mMTris pH 8.3, 250 mM glycine, 20% v/v methanol).

After transfer, the membrane was placed in 20 mL Sensitizer (12 mM HCl) for 5 min, and the solution was removed. It was placed in 20 mL CPTS dye ((Copper(II) phthalocyanine-3,4’,4”,4‴-tetrasulfonic acid tetrasodium salt (50 mg in 100 mL 12 mM HCl)), and was stirred strongly for protein staining. The dye was removed and
the membrane washed with Sensitizer before being digitalized with a scanner (HP Scanjet G4050). The stained proteins were removed with Eraser solution (50 mL 0.2 M KCl + 40.8 mL 0.2 M NaOH, pH 12.5).

**ImmunoBlot**

The nitrocellulose membrane was blocked with 30 mL 5% non-fat dry milk in PBS + Tween 20 (0.03%) at pH 7.4 and stirred overnight at 4°C. The next day the milk was removed and 5 mL skim milk in PBS-Tween and the primary Ab mouse serum (1:250) were placed and stirred for 4 h at room temperature. Four washes each for 10 min each of 20 mL PBS-Tween were use.

Bound antibodies were detected by incubation (1 h at room temperature) with HRP-conjugated secondary antibody (goat anti-IgG or IgM mouse, ZIMED), diluted 1/2500 in PBS-Tween 20. Each was washed 4 times for 10 min with 20 mL PBS-Tween. Detection of second antibody binding was by incubation with DAB substrate (3, 3′-diaminobenzidine; 0.5 mg/mL; 10 min) and 10 μL hydrogen peroxide.

**Image processing**

From duplicates of the resulting 2D-immunoblot images, a master image was created, which was analyzed by counting the total number of spots (Σ spots) or the number of unique spots per week were counted. Exclusive spots were obtained by subtracting the antigens recognized at t = 0, which had coincidence in isoelectric point and molecular weight, and were also detected at subsequent weeks of tumor development. Immunoblots were digitalized using an HP Scanjet G40505 scanner with a resolution level of 300 DPI in a TIFF format. The TIF images were transferred to Adobe Photoshop for counting of spots, identification of coordinates of each spot in the 2D-immunoblot, and the calculation of the perimeters of the spots, location of the coordinates and the centroids. All 2D-immunoblots were analyzed at the same settings of brightness, contrast, and color to minimize bias.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

MDZ has a doctoral fellowship from the Consejo Nacional de Ciencia y Tecnología, México. RH is a master of science and has an academic position at the Instituto de Investigaciones Biomédicas. POS is a PhD in Biochemistry and is a researcher at the Instituto de Investigaciones Biomédicas. All work at the Universidad Nacional Autónoma de México.

**Acknowledgements**

Financial support was provided by Grant # 151747 (Pedro Ostoa-Saloma) from Consejo Nacional de Ciencia y Tecnología, México and #N204311-3 (Pedro Ostoa Saloma) from Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (PAPIIT), DGAPA Universidad Nacional Autónoma de México. This paper is in partial fulfillment of the Graduate Program in Biological Sciences of the National Autonomous University of Mexico (UNAM), M. Díaz-Zaragoza acknowledges the scholarship and financial support provided by the National Council of Science and Technology (CONACyT), and UNAM.

**References**

1. Vollmers HP, Brändlein S: Natural IgM antibodies: from pariahs to parvenus. *Hotz Histopathol* 2006, 21:1355–1356.
2. Dunn GP, et al: The immunobiology of cancer immunosurveillance and immunediting. *Immunity* 2004, 21:137–14.
3. Llanes-Fernández L, Alvarez-Goyanes R, Del Arango-Prado MC, Alcocer-González JM, Mojarrieta JC, Pérez XE, López MO, Oslo SF, Camacho-Rodríguez R, Guerra-Yi ME, Madrid-Marina V, Tamez-Guerra R, Rodriguez-Padilla C: Relationship between IL-10 and tumor markers in breast cancer patients. *Breast* 2006, 18:482–489.
4. Roberts MA, Bass EM, Wallace IW, Stevenson A: Local immunoglobulin production in breast cancer. *Br J Cancer* 1973, 27:269–275.
5. Tagliaferri M, Cohen I, Tripathy D: Complementary and alternative medicine in early-stage breast cancer. *Semin Oncol* 2001, 28:121–134.
6. Gain Mi, Chu CC, Golshayan D, Cernuda-Morollón E, Waite R, Lechter RI: Galectin-1: a key effector of regulation mediated by CD4 + CD25+ T cells. *Blood* 2007, 109:2058–2065.
7. Dalotto-Moreno T, Croci DO, Gerlani JP, Martinez-Allo VC, Degan-Dyson S, Méndez-Huengo SP, Stupinski X, Mazal D, Díazna E, Toscano MA, Sundblad V, Rabirnovich GA, Salatino M: Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. *Cancer Res* 2013, 73:1107–1117.
8. Shishido SN, Varahan S, Yuan K, Li X, Fleming SD: Humoral innate immune response and disease. *Clin Immunol* 2012, 144:142–158.
9. Hensel F, Herrmann R, Schubert C, Abé N, Schmidt K, Franke A, Shevchenko A, Mann M, Müller-Hermelink HK, Vollmers HP: Characterization of glycosylphosphatidylinositol-linked molecule CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in cancer-associated immunosuppression and prevents metastatic disease. *Blood* 2007, 109:2058–2065.
10. Hao M, Guo X, Shen L, Li L, Li M, Wang Y, Liu S, He L, Li X, Zhuang W, Jing X, Wang X, Cai Y, Yang D, Zhang P, Zhang F, Wang H: The RER of colon cancer cells. *J Cell Sci* 2011, 124:3345–3353.
11. Glennie MJ, Van de Winkel JG: The immunobiology of cancer immunosurveillance and immunediting. *Hum Antibodies* 1999, 39:5299–5306.
12. Hensel F, Herrmann R, Brändlein S, Kien V, Schmauss B, Geis S, Müller-Hermelink HK, Vollmers HP: Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1-induced apoptosis. *Lab Inver* 2001, 81:1553–1563.
13. Gennie MJ, Van de Winkel JG: Renaissance of cancer therapeutic antibodies. *Drug Discov Today* 2003, 8:503–510.
14. Brändlein S, Lorenz J, Ruoff N, Hensel F, Beyer J, Müller J, Neuhaus K, Hettinger T, Eck M, Müller-Hermelink HK, Vollmers HP: Characterization of glycosylphosphatidylinositol-linked molecule CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1-induced apoptosis. *Lab Inver* 2001, 81:1553–1563.
15. Lloyd KD, Old LJ: Human monoclonal antibodies to glycolipids and other carbohydrate antigens: dissection of the humoral immune response in cancer patients. *Cancer Res* 2009, 69:5109–5116.
16. Turner GA: N-glycosylation of serum proteins in disease and its investigation using lectins. *Clin Chim Acta* 1992, 208:149–171.
17. Hensel F, Brandlein S, Eck M, Schmidt K, Knenn V, Kloetzer A, Bach A, Mann M, Müller-Hermelink HK, Vollmers HP: A novel proliferation-associated variant of CFR-1 defined by a human monoclonal antibody. Lab Invest 2001, 81:1097–1108.

18. Brändlein S, Pohle T, Ruoff N, Wozniak E, Müller-Hermelink HK, Vollmers HP: Natural IgM antibodies and immunosurveillance: mechanisms against epithelial cancer cells in humans. Cancer Res 2003, 63:7995–8005.

19. Brändlein S, Vollmers HP: Natural IgM antibodies, the ignored weapons in tumour immunity. Histol Histopathol 2004, 19:897–905.

20. Bachmann MF, Rohrer UH, Kundig TM, Burgi K, Hengartner H, Zinkernagel RA: The influence of antigen organization on B cell responsiveness. Science 1999, 286:1448–1451.

21. Mond JJ, Vos Q, Lees A, Snapper CM: T cell independent antigens. Curr Opin Immunol 1995, 7:349–354.

22. Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ: B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 2000, 176:154–170.

23. Sokoloff AV, Bock I, Zhang G, Hoffman S, Dama J, Ludtke JJ, Cooke AM, Wolff JA: Specific recognition of protein carboxy-terminal sequences by natural IgM antibodies in normal serum. Mol Ther 2001, 3:821–830.

24. Coutinho A, Kazatchkine MD, Avrameas S: Natural autoantibodies. Curr Opin Immunol 1995, 7:812–818.

25. Baumgarth N, Herman OC, Jager GC, Herzenberg LA, Herzenberg LA: Innate and acquired immunities to influenza virus are provided by distinct B cells. Proc Natl Acad Sci U S A 1999, 96:2250–2255.

doi:10.1186/1475-2867-14-9
Cite this article as: Díaz-Zaragoza et al.: 2D immunoblots show differential response of mouse IgG and IgM antibodies to antigens of mammary carcinoma 4 T1 cells. Cancer Cell International 2014 14:9.